Tulba, Sherwin O.
HRN: 23-82-88 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/06/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/06/2023
10/12/2023
IVTT
2.25 G
Q8
Brain Abscess
Waiting Final Action
Indication: EmpiricEmpirical Escalation Type of Infection: Central Nervous System Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes